Iterum Therapeutics plc (ITRMF): Nasdaq/NYSE listing notice — Iterum Therapeutics receives Nasdaq delisting notice for MVLS below $35M

Iterum Therapeutics plc

Nasdaq notified Iterum on Dec 11, 2025 that MVLS <$35M for 30 consecutive business days; given 180 days until June 9, 2026 to regain compliance.
Company also remains out of compliance with $1.00 minimum bid price rule since August 2025, with compliance period ending Feb 23, 2026.
Failure to cure either deficiency could lead to delisting; company may appeal but no assurance of success.
Notice has no immediate effect on listing; common stock continues trading on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

August 25, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq granted the Company 180 calendar days, through February 23, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Company’s ordinary shares be at least $1.00 for a minimum of 10 consecutive business days. The Company remains out of co

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-25-317728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.